Residency · Residency · Urology

Surgical Management of Stress Urinary Incontinence

Overview

Surgical intervention for stress urinary incontinence (SUI) is typically considered when conservative treatments such as pelvic floor muscle training (PFMT), weight loss, or pessary use have failed, or when the patient opts for a definitive solution. The primary goal of surgery is to restore adequate urethral support and/or enhance urethral coaptation to prevent leakage. Among the various surgical options, the midurethral sling (MUS) procedure is the most commonly performed worldwide. The choice of surgical technique depends on the underlying mechanism of incontinence—whether due to urethral hypermobility or intrinsic sphincter deficiency (ISD)—as well as prior surgeries, patient-specific factors, and the surgeon’s expertise.

Midurethral Sling (MUS)

Retropubic Midurethral Sling (TVT - Tension-free Vaginal Tape)

The retropubic midurethral sling involves placing a polypropylene mesh tape at the mid-urethra through the retropubic space. This can be performed using either a bottom-up or top-down approach. A trocar is passed from a vaginal incision through the endopelvic fascia and retropubic space, exiting through suprapubic incisions. Intraoperative cystoscopy is mandatory during this procedure to exclude bladder perforation, which occurs in approximately 2-5% of cases. The mechanism of action is the creation of a suburethral hammock that compresses the urethra during increases in intra-abdominal pressure, such as during Valsalva maneuvers. The retropubic sling demonstrates a high cure rate, with objective success between 80-90% and subjective success between 85-95% at five years postoperatively.

Transobturator Midurethral Sling (TOT/TVT-O)

The transobturator midurethral sling involves passing the mesh tape through the obturator foramen, using either an outside-in (TOT) or inside-out (TVT-O) approach. This technique avoids the retropubic space, thereby reducing the risk of bladder perforation to less than 1%, as well as minimizing the risk of bowel or major vascular injury. However, there is a higher incidence of groin or thigh pain (2-5%) due to the proximity of the obturator nerve. Although cystoscopy is recommended, bladder injury is very rare with this approach. The cure rates for transobturator slings are comparable to retropubic slings, ranging from 80-90%.

Retropubic vs. Transobturator: Key Differences

When comparing retropubic and transobturator slings, retropubic slings have a higher risk of bladder perforation (2-5%) compared to less than 1% with transobturator slings. Groin pain is rare with retropubic slings but occurs in 2-5% of transobturator cases. Vascular injury, while rare, is more serious with retropubic slings and very rare with transobturator slings. Voiding dysfunction is slightly more common after retropubic sling placement, whereas transobturator slings have a slightly lower incidence. Retropubic slings may be more effective in treating ISD, given their greater obstructive effect, and both approaches have good efficacy when used for repeat surgeries. For patients with ISD characterized by low Valsalva leak point pressure (VLPP <60 cmH2O) or low maximum urethral closure pressure (MUCP <20 cmH2O), some evidence suggests that retropubic slings may be superior.

Single-Incision Mini-Slings

Single-incision mini-slings use a shorter mesh that is anchored in the obturator membrane, with examples including MiniArc and Altis devices. The theoretical advantage of these slings is the use of less mesh and a single vaginal incision, potentially reducing morbidity. However, outcomes in studies have been variable, with some showing comparable results to traditional slings. Due to this variability, mini-slings are not universally recommended as first-line treatment.

<image>Comparative anatomic diagrams showing retropubic midurethral sling (TVT) trajectory through the retropubic space and transobturator sling (TOT) trajectory through the obturator foramen</image>

Autologous Fascial Sling (Pubovaginal Sling)

Technique

The autologous fascial sling involves harvesting a graft of rectus fascia (or alternatively fascia lata from the thigh) which is then placed at the bladder neck rather than the mid-urethra. Suspending sutures are passed through the retropubic space and tied over the rectus fascia to provide support. Cystoscopy is mandatory during this procedure to ensure no bladder injury occurs.

Indications

This technique is particularly indicated for intrinsic sphincter deficiency, either as a primary treatment or after failed synthetic sling surgery. It is also preferred by patients who wish to avoid synthetic mesh, and it is commonly used in revision or redo anti-incontinence surgeries. Additionally, it is suitable for patients with concomitant urethral pathology such as diverticulum repair or fistula, as well as those with neurogenic stress urinary incontinence.

Outcomes

The autologous fascial sling has a cure rate of 80-90%, comparable to synthetic slings. However, it is associated with a higher incidence of de novo urgency and voiding dysfunction due to compression at the bladder neck. This procedure is more invasive and requires a longer recovery period than midurethral slings but avoids mesh-related complications entirely.

Burch Colposuspension

Technique

Burch colposuspension can be performed via open, laparoscopic, or robotic approaches. The procedure involves suturing paravaginal tissue to Cooper’s ligament (also known as the iliopectineal ligament), thereby elevating and stabilizing the bladder neck. Historically, this was considered the gold standard surgical treatment for SUI before the advent of sling procedures.

Indications

Burch colposuspension serves as an alternative to sling procedures when mesh is contraindicated or declined by the patient. It can also be performed concurrently with abdominal sacrocolpopexy for pelvic organ prolapse. However, it is less commonly performed as a primary procedure today.

Outcomes

The cure rate for Burch colposuspension ranges from 70-85% at five years, which is slightly lower than that of midurethral slings in comparative trials. It carries a lower risk of voiding dysfunction than the fascial sling but has a higher risk of de novo pelvic organ prolapse, including enterocele and cystocele formation.

<image>Operative photograph and diagram of Burch colposuspension showing suture placement from paravaginal tissue to Cooper's ligament bilaterally</image>

Urethral Bulking Agents

Technique

Urethral bulking agents are injected transurethrally into the periurethral tissue at the bladder neck to improve urethral coaptation. Common agents include Bulkamid (polyacrylamide hydrogel) and Macroplastique (silicone), while collagen is no longer available. This is typically an office-based procedure performed under local anesthesia. Multiple injection sessions are often necessary to achieve optimal results.

Indications

Bulking agents are primarily indicated for intrinsic sphincter deficiency, either as a primary treatment or adjunctive therapy. They are suitable for elderly or frail patients who are poor candidates for surgery, those who have failed prior anti-incontinence surgery, or patients who prefer a minimally invasive option. Bulking agents may also serve as temporary or bridge therapy.

Outcomes

The cure rate with bulking agents is lower than with sling or Burch procedures, ranging from 20-40%, although improvement rates are higher at 50-70%. Durability is limited, with repeat injections required in 40-60% of patients at two years. Complication rates are very low, and among available agents, Bulkamid currently has the best evidence for durability.

Artificial Urinary Sphincter (AUS) in Women

The artificial urinary sphincter is rarely used in women and is reserved for severe, refractory intrinsic sphincter deficiency. The cuff is placed around the bladder neck. However, women experience higher rates of revision and erosion compared to men. An alternative to AUS is adjustable continence therapy (ProACT).

Mesh Complications and Regulatory Landscape

Mesh-Related Complications

Complications related to mesh include vaginal mesh exposure or erosion, which occurs in 1-5% of cases and presents with symptoms such as vaginal discharge, pain, dyspareunia, or partner discomfort. Management ranges from observation for small, asymptomatic exposures to office trimming or surgical excision. Urinary tract perforation or erosion occurs when mesh erodes into the bladder or urethra, necessitating surgical removal. Pain syndromes involving the groin, thigh, or pelvis may be neuropathic in nature. Voiding dysfunction or obstruction can occur if the sling is too tight, sometimes requiring sling incision or loosening. Infection is rare but may require mesh removal. De novo urgency or overactive bladder symptoms develop in 5-15% of patients.

Regulatory Actions

In 2016, the FDA reclassified surgical mesh for SUI as Class II. Transvaginal mesh for pelvic organ prolapse was removed from the market in 2019; however, this restriction does not apply to midurethral slings for SUI. Midurethral slings remain available and are recommended by all major guideline societies, including the AUA, EAU, and NICE. Informed consent must include a discussion of mesh-specific risks.

<image>Intraoperative cystoscopic view confirming no mesh perforation during retropubic sling placement, and a clinical photograph of vaginal mesh exposure requiring revision</image>

Postoperative Care and Follow-Up

Midurethral sling surgery is typically performed as a same-day or overnight procedure. Before discharge, a voiding trial is conducted by filling the bladder to 300 mL and measuring voided volume and post-void residual (PVR). If the PVR exceeds 100-150 mL or the voided volume is less than 200 mL, patients are taught clean intermittent catheterization (CIC) and re-evaluated in 1-2 weeks. Patients should avoid heavy lifting greater than 10 pounds for six weeks. Follow-up visits are scheduled at 2-4 weeks and then at 3-6 months postoperatively. Long-term annual follow-up is recommended to monitor for mesh-related complications.

Special Scenarios

In cases of concomitant pelvic organ prolapse, both prolapse and SUI should be addressed simultaneously if indicated. Reducing the prolapse during stress testing can help unmask occult SUI. For patients with failed prior sling surgery, options include repeat sling placement at a different location, autologous fascial sling, bulking agents, or sling revision. Obese patients should be encouraged to lose weight first, as a 5-10% reduction in weight can decrease SUI by 50%. Sling outcomes in obese patients are generally good but slightly lower than in non-obese individuals. Elderly patients may benefit from bulking agents or pessary use, though midurethral slings remain safe with appropriate patient selection. For neurogenic SUI, the fascial sling placed at the bladder neck is preferred.

Clinical Pearls

Midurethral slings, both retropubic and transobturator, remain the standard of care for stress urinary incontinence. It is important to note that FDA regulatory actions targeted transvaginal mesh for pelvic organ prolapse, not midurethral slings for SUI. Intraoperative cystoscopy is mandatory during retropubic sling placement and recommended during transobturator sling procedures. For patients with intrinsic sphincter deficiency characterized by low VLPP or MUCP, retropubic slings or autologous fascial slings should be considered, as transobturator slings may be less effective. Postoperative voiding dysfunction occurs in 2-5% of cases and is usually transient; persistent obstruction may require sling incision. The most significant complication to counsel patients about is mesh exposure, which occurs in approximately 2-3% of cases and is often manageable with office trimming. The autologous fascial sling remains the gold standard for redo anti-incontinence surgery and for patients who prefer to avoid synthetic mesh.

References

• AUA/SUFU Guideline on Surgical Treatment of Female Stress Urinary Incontinence, 2017 (amended 2023)
• EAU Guidelines on Urinary Incontinence, 2024 Update
• Ford AA, et al. "Mid-urethral sling operations for stress urinary incontinence." Cochrane Database Syst Rev. 2017.
• Richter HE, et al. "Retropubic versus transobturator midurethral slings" (TOMUS Trial). NEJM. 2010;362(22):2066-2076.
• FDA Safety Communication on Surgical Mesh for SUI, 2016
• Campbell-Walsh-Wein Urology, 12th Edition, Chapter on Surgical Management of SUI

Read this lecture as Markdown